New research suggests that patients who stop using new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight at a significantly accelerated pace than those who stop conventional diet and exercise regimens.
Findings released in a prominent medical journal points out that while overweight people often shed a large proportion of their total mass while on the medication, the mass returns at an average rate of 0.8 kg per month once they quit.
"Users purchasing such treatments should be cognizant of the danger of fast rebound weight gain when the medication concludes," warns expert Dr. Susan Jebb.
That rate of recovery implies a reversion to starting mass within about a year and a half.
Comparing Approaches
The analysis, which examined dozens of studies involving thousands of participants, contrasted the effects of GLP-1 agonists with older methods.
The team emphasize that people who shed pounds through diet and exercise typically have a more gradual weight regain—approximately 0.1 kg a month—post-intervention.
Explaining the Fast Regain
Experts believe the mechanism of the drugs accounts for the accelerated regain.
GLP-1 drugs copy a body's own chemical called GLP-1, which moderates hunger.
"Artificially providing GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous GLP-1, and could lessen sensitivity to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this medication means hunger is no longer kept in check, making binge eating much more probable."
An Ongoing Condition?
Health authorities recommend the jabs for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts say that, considering the high risk of relapse, the therapy might need to be life-long.
This opinion is reinforced by pharmaceutical companies, who say that the findings "highlight the long-term character of excess weight," comparing it to managing diseases like diabetes.
User Accounts
Users who have come off the medication report a sudden resurgence of cravings.
"It felt as if something that goes on and you're instantly starving," described a patient.
The struggle is exacerbated if patients have not established permanent dietary or behavioural changes during treatment.
Growing Adoption
Recent estimates indicate that millions of people in the UK have tried these injections in the past year, with demand being substantial.
- Use is greater among females compared to men.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
In conclusion, experts caution that while the jabs are potent tools for weight loss, they are not a magic cure and long-term success likely depends on integrated behavioural support.
